PneuMedicare has raised $1.25 million in a first round of financing. The investor is Globe Group. PneuMedicare is developing a medical device for continuous monitoring of lung ventilation in mechanically ventilated patients. Founded in 2007, the company is a graduate of the Yozmot HaEmek Ltd. incubator (formerly known as Ofek LaOleh Jezre’el Valley Initiative Center). PneuMedicare’s device warns on changes in lung ventilation or air distribution in the lungs in earlier stages, before the development of life threatening deteriorations due to decrease in blood oxygenation. http://www.globes.co.il/serveen/globes/docview.asp?did=1000571076&fid=1725
Healthcare / Biotech News
Lung monitor co PneuMedicare raises $1.25m
Thursday, July 1st, 2010Prolor rises on growth hormone production permit
Wednesday, June 30th, 2010Prolor Biotech Inc. has obtained formal Good Manufacturing Practice (GMP) certification for its hGH-CTP human growth hormone. GMP certification is required by EU clinical trials legislation as a precondition for conducting clinical trials in EU member countries. hGH-CTP is a proprietary biobetter therapeutic protein for the long-term treatment of children and adults with growth hormone deficiency due to inadequate secretion of endogenous growth hormone. The drug can be injected weekly or monthly, compared with the daily injections needed for current products. The company estimates global sales of growth hormone products at $3 billion a year. http://www.globes.co.il/serveen/globes/docview.asp?did=1000570538&fid=1725
Perrigo buys US rights to generic Allegra from Teva
Wednesday, June 30th, 2010Perrigo Company has acquired the exclusive US rights to generic Allegra from Teva Pharmaceutical Industries Ltd.. Perrigo sell and distribute store brand and over-the-counter versions of the drug, after Teva and Sanofi-Aventis settled litigation over it. Allegra is a treatment for seasonal allergies. Brand versions of the prescription drug had $2.1 billion in US sales altogether in 2009. http://www.globes.co.il/serveen/globes/docview.asp?did=1000570539&fid=1725
AmerisourceBergen to distribute Kamada’s AAT in US
Tuesday, June 22nd, 2010The US distributor has promised to sell at least $15 million worth of Glassia in the first 18 months after Kamada gets FDA approval.
Sources inform ”Globes” that AmerisourceBergen Corporation will be the US distributor for Kamada Ltd’s intravenous AAT (Alpha-1 Antitrypsin) drug for congenital respiratory diseases, which received the commercial name “Glassia” earlier this week. AmerisourceBergen is one of the largest pharmaceutical and medical services distributors in North America and the UK. http://www.globes.co.il/serveen/globes/docview.asp?did=1000559093&fid=1725
